Lumigan (bimatoprost) / Senju, AbbVie 
Welcome,         Profile    Billing    Logout  
 0 Diseases   17 Trials   17 Trials   629 News 


«12345678910»
  • ||||||||||  Lumigan (bimatoprost) / Senju, AbbVie
    Trial completion:  Topical Bimatoprost for Chemical Blepharoplasty (clinicaltrials.gov) -  Mar 5, 2021   
    P1,  N=15, Completed, 
    NCT02471105. Active, not recruiting --> Completed
  • ||||||||||  Lumigan (bimatoprost) / Senju, AbbVie, Zioptan (tafluprost) / Santen, Merck (MSD)
    Reimbursement, Journal, Medicare:  Prostaglandin Coverage and Costs to Medicare and Medicare Beneficiaries, 2009-2017. (Pubmed Central) -  Jan 8, 2021   
    Medicare PDP coverage of branded prostaglandins remained stable from 2009 to 2017. While median beneficiary out-of-pocket costs associated with generic prostaglandins remained stable, those associated with branded prostaglandins increased nearly 3-fold.
  • ||||||||||  Lumigan (bimatoprost) / Senju, AbbVie, Durysta (bimatoprost implant) / AbbVie
    [VIRTUAL] PO181: Single Administration of Intracameral Bimatoprost Implant 10 μg: IOP Lowering and Safety () -  Nov 11, 2020 - Abstract #AAO2020AAO_298;    
    At Week 15 (final IOP measurement after single administration), BimSR patients had mean IOP of 18.8 ± 4.4 mmHg; 61% of them had ≥20% IOP lowering, and only 2.1% had been rescued. Conclusion A single BimSR implant effectively lowered IOP for 15 weeks with an acceptable corneal safety profile and potential for an extended duration of effect.
  • ||||||||||  Azopt (brinzolamide ophthalmic suspension 1%) / Novartis, Lumigan (bimatoprost) / Senju, AbbVie
    Journal:  Corneal sterile infiltration induced by topical use of ocular hypotensive agent. (Pubmed Central) -  Oct 27, 2020   
    A diagnosis of glaucoma was made 2 years previously, and anti-glaucoma agents were prescribed (brimonidine tartrate, ripasudil hydrochloride hydrate, and brinzolamide) for both eyes...A diagnosis of glaucoma was made 35 years previously, and anti-glaucoma agents were prescribed (brimonidine tartrate, 1% dorzolamide, and bimatoprost) for both eyes...The three topical drugs were discontinued and replaced with 0.1% fluorometholone...We encountered two cases of corneal and conjunctival complications that were suspected as side effects after brimonidine eye drop use. Special care should be taken to observe the condition of ocular surface when topical brimonidine is administered.
  • ||||||||||  Lumigan (bimatoprost) / Senju, AbbVie, Durysta (bimatoprost implant) / AbbVie
    Review, Journal:  Bimatoprost Implant: First Approval. (Pubmed Central) -  Oct 27, 2020   
    Allergan's clinical development programme for bimatoprost implant is ongoing. This article summarizes the milestones in the development of bimatoprost implant leading to this first approval for use in the reduction of IOP in patients with OAG or OHT.
  • ||||||||||  Eylea (aflibercept intravitreal) / Bayer, Regeneron, Lumigan (bimatoprost) / Senju, AbbVie
    [VIRTUAL] Diagnosis and Management of a Non-Ischemic Central Retinal Vein Occlusion (Track 1 - Academy at Home) -  Oct 14, 2020 - Abstract #AAOPT2020AAOPT_554;    
    History is as follows:Systemic History: HTN, Hyperlipidemia (HLD)Ocular History: Chronic Angle Closure Glaucoma-Mild OU, Cataracts and Retinal Vascular ChangesSystemic Medications: Hydrochlorothiazide, Ursodiol, Metoprolol Tartrate, Verapamil, Lisinopril, BenicarOcular Medications: Lumigan and Dorzolamide OU Pertinent Findings At the initial examination, VAs were 20/60-2 OD (PHNI) and 20/25 OS...At which time, the patient was given an intravitreal Eylea injection.Treatment options that have been investigated for ME in CRVO include: grid laser, intravitreal triamcinolone injections, anti-VEGF injections, and intravitreal steroid implants...Due to the increase risk of elevated IOP and development of cataracts, intravitreal steroid implantation is typically reserved for pseudophakic patients who are unable to be successfully treated with anti-VEGF. Conclusion A patient with CRVO should be closely monitored with frequent gonioscopy due to their risk of developing NVG. It is important to communicate with the patient’s primary care physician to ensure that their underlying systemic conditions are well controlled.
  • ||||||||||  Lumigan (bimatoprost) / Senju, AbbVie
    [VIRTUAL] Not the Usual Suspect, Culturing Rare Bacteria in a Severe Corneal Ulcer (Track 1 - Academy at Home) -  Oct 14, 2020 - Abstract #AAOPT2020AAOPT_355;    
    She also has associated symptoms of headaches and watery discharge.She has history of open angle glaucoma controlled with Combigan and Lumigan and has significant vision loss right eye (OD) secondary to proliferative diabetic retinopathy...At the following visit she received an intrastromal injection of fortified vancomycin and topical moxifloxacin was added...Although endothelial plaques are most commonly associated with fungi, cultures proved otherwise in this case. Uncommon pathogens that progress aggressively require a multiprong approach in treatment.
  • ||||||||||  Lumigan (bimatoprost) / Senju, AbbVie, Vyzulta (latanoprostene bunod) / Bausch Health, Nicox
    [VIRTUAL] Cost per Responder Analysis of Latanoprostene Bunod Compared to Prostaglandin Analogs for OPEN-Angle Glaucoma in Canada () -  Oct 3, 2020 - Abstract #ISPOREU2020ISPOR-EU_1128;    
    OBJECTIVES: The aim of this study was to estimate the cost per responder in the reduction of intraocular pressure (IOP) in patients with open-angle glaucoma (OAG) or ocular hypertension for latanoprostene bunod (LBN) compared to other prostaglandin analogs (PGAs) from a Canadian perspective. LBN is associated with a favourable cost per responder and cost per non-responder compared to other PGAs available in Canada to reduce IOP in patients with OAG or ocular hypertension.
  • ||||||||||  Lumigan (bimatoprost) / Senju, AbbVie, Zioptan (tafluprost) / Santen, Merck (MSD)
    Journal, Monotherapy:  An in vivo confocal, prospective, masked, 36 months study on glaucoma patients medically treated with preservative-free or preserved monotherapy. (Pubmed Central) -  Sep 30, 2020   
    Endothelial density values were statistically different at baseline (p = 0.007), they decreased both in PF-group and in S-group (p = 0.048 and 0.001, respectively), while increased in P-group (p = 0.006). Our study is the first to show that a PF-tafluprost formulation does not significantly alter the corneal structures as examined by confocal microscopy after 36 months of topical daily therapy, while improving corneal alterations due to chronic preserved therapies.
  • ||||||||||  Journal:  Durysta - a bimatoprost implant for glaucoma. (Pubmed Central) -  Sep 20, 2020   
    These findings have potential implications for the treatment of exophthalmos in the clinical setting, but more research is required. No abstract available